Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Progyny PGNY in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 4 | 5 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 1 | 2 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 3 | 2 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Progyny, presenting an average target of $21.0, a high estimate of $26.00, and a low estimate of $17.00. This current average has decreased by 22.22% from the previous average price target of $27.00.
Investigating Analyst Ratings: An Elaborate Study
The standing of Progyny among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Anne Samuel | JP Morgan | Lowers | Neutral | $17.00 | $22.00 |
| Sarah James | Barclays | Lowers | Overweight | $17.00 | $30.00 |
| Michael Cherny | B of A Securities | Lowers | Buy | $21.00 | $22.00 |
| Richard Close | Canaccord Genuity | Lowers | Hold | $17.00 | $18.00 |
| Jailendra Singh | Truist Securities | Lowers | Hold | $19.00 | $26.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $25.00 | $25.00 |
| Richard Close | Canaccord Genuity | Lowers | Hold | $18.00 | $24.00 |
| Glen Santangelo | Jefferies | Lowers | Buy | $24.00 | $31.00 |
| Jailendra Singh | Truist Securities | Lowers | Buy | $26.00 | $33.00 |
| Anne Samuel | JP Morgan | Lowers | Overweight | $22.00 | $31.00 |
| Sarah James | Cantor Fitzgerald | Lowers | Overweight | $25.00 | $37.00 |
| Michael Cherny | Leerink Partners | Lowers | Market Perform | $21.00 | $25.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Progyny. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Progyny compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Progyny's stock. This examination reveals shifts in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Progyny's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Progyny analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Progyny
Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.
Breaking Down Progyny's Financial Performance
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Progyny's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 2.04%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 3.64%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Progyny's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.34%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Progyny's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.53% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Progyny's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.04.
Analyst Ratings: Simplified
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
